Frontiers in Pharmacology (Oct 2022)
The combination of Chinese and Western Medicine in the management of rheumatoid arthritis: A real-world cohort study across China
- Linda LD. Zhong,
- Linda LD. Zhong,
- Linda LD. Zhong,
- Rongsheng Wang,
- Rongsheng Wang,
- Wai Ching Lam,
- Qi Zhu,
- Qi Zhu,
- Peipei Du,
- Pei Hua Cao,
- Ting Jiang,
- Ting Jiang,
- Yuan Yuan Zhang,
- Yuan Yuan Zhang,
- Jie Shen,
- Jie Shen,
- Xiao Su,
- Luan Xue,
- Jianchun Mao,
- Yong Fei Fang,
- Ming Li Gao,
- Chun Rong Hu,
- Jiang Yun Peng,
- Ying Gu,
- Qianghua Wei,
- Runyue Huang,
- Runyue Huang,
- Runyue Huang,
- Runyue Huang,
- Aiping Lyu,
- Aiping Lyu,
- Hongxia Liu,
- Dongyi He,
- Dongyi He
Affiliations
- Linda LD. Zhong
- School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
- Linda LD. Zhong
- School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
- Linda LD. Zhong
- Department of Rheumatology, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Hong Kong, China
- Rongsheng Wang
- Department of Medicine, ShangHai GuangHua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China
- Rongsheng Wang
- Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China
- Wai Ching Lam
- School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
- Qi Zhu
- Department of Medicine, ShangHai GuangHua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China
- Qi Zhu
- Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China
- Peipei Du
- School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
- Pei Hua Cao
- School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
- Ting Jiang
- Department of Medicine, ShangHai GuangHua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China
- Ting Jiang
- Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China
- Yuan Yuan Zhang
- Department of Medicine, ShangHai GuangHua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China
- Yuan Yuan Zhang
- Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China
- Jie Shen
- Department of Medicine, ShangHai GuangHua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China
- Jie Shen
- Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China
- Xiao Su
- Department of Rheumatology and Immunology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China
- Luan Xue
- Department of Rheumatology and Immunology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- Jianchun Mao
- Department of Rheumatology, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China
- Yong Fei Fang
- Department of Rheumatology, Southwest Hospital, Chongqing, China
- Ming Li Gao
- 0Department of Rheumatology, Liaoning Hospital of Traditional Chinese Medicine, Liaoning, China
- Chun Rong Hu
- 1Department of Rheumatology, The Ninth People’s Hospital of Chongqing, Chongqing, China
- Jiang Yun Peng
- 2Department of Rheumatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Yunnan, China
- Ying Gu
- 3Department of Rheumatology, Mianyang Hospital of Traditional Chinese Medicine, Sichuan, China
- Qianghua Wei
- 4Department of Rheumatology, Shanghai General Hospital, Shanghai, China
- Runyue Huang
- Department of Rheumatology, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Hong Kong, China
- Runyue Huang
- 5The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China
- Runyue Huang
- 6State Key Laboratory of Dampness Syndrome of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangzhou, China
- Runyue Huang
- 7Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China
- Aiping Lyu
- School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
- Aiping Lyu
- Department of Rheumatology, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Hong Kong, China
- Hongxia Liu
- 8Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- Dongyi He
- Department of Medicine, ShangHai GuangHua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China
- Dongyi He
- Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China
- DOI
- https://doi.org/10.3389/fphar.2022.933519
- Journal volume & issue
-
Vol. 13
Abstract
Objective: To investigate the efficacy of Integrative medicine (IM), compare with Western medicine (WM), in the treatment of rheumatoid arthritis (RA) in a cohort study.Methods: This is a cohort study with recruitment of RA patients from 10 hospitals in China. The primary outcome was change in disease activity score 28 (DAS28) during 4 follow-up visits. Generalized estimating equation (GEE) models that controlled for variables were used to investigate a time trend and assess group differences in the primary outcome and secondary outcomes after propensity score matching (PSM).Results: A total of 3195 patients with RA received IM (n = 1379, 43.2%) or WM (n = 1816, 56.8%). Following 1:1 propensity score matching, 1,331 eligible patients prescribed IM were compared to 1,331 matched patients prescribed WM. The GEE analysis with PSM showed that the IM was more beneficial to significantly decrease the levels of VAS, PGA and PhGA (VAS: odds ratio (OR), 0.76; 95% CI, 0.63–0.92; p = 0.004; PGA: OR, 0.76; 95% CI, 0.64–0.92; p = 0.007; and PhGA: OR, 0.77; 95% CI, 0.64, 0.93; p = 0.004), and reduce DAS28 (OR, 0.84; 95% CI, 0.73–0.98; p = 0.030) in the per-protocol population.Conclusion: This study suggests that compare to WM, IM has advantages in improving RA-related outcomes. However, the statistical significance might not reveal significant clinical difference. Further studies should be focused on specific treatment strategies and/or disease stages.
Keywords
